| Unmutated RRAS2 emerges as a key oncogene in post-partum-associated triple negative breast cancer. | Unmutated RRAS2 emerges as a key oncogene in post-partum-associated triple negative breast cancer.
Cifuentes C, Oeste CL, Fernández-Pisonero I, Hortal AM, García-Macías C, Hochart J, Rubira R, Horndler L, Horndler C, Bustelo XR, Alarcón B., Free PMC Article | 08/2/2024 |
| Characterization of Three Somatic Mutations in the 3'UTR of RRAS2 and Their Inverse Correlation with Lymphocytosis in Chronic Lymphocytic Leukemia. | Characterization of Three Somatic Mutations in the 3'UTR of RRAS2 and Their Inverse Correlation with Lymphocytosis in Chronic Lymphocytic Leukemia.
Lacuna M, Hortal AM, Cifuentes C, Gonzalo T, Alcoceba M, Bastos M, Bustelo XR, González M, Alarcón B., Free PMC Article | 04/2/2024 |
| The RRAS2 pathogenic variant (c.67G>T; p. Gly23Cys) produces Noonan syndrome with embryonal rhabdomyosarcoma. | The RRAS2 pathogenic variant (c.67G>T; p. Gly23Cys) produces Noonan syndrome with embryonal rhabdomyosarcoma.
Zeng L, Wang J, Zhu H, Huang Y, Deng Y, Wei P, Nie J, Tang B, Chen A, Zhu S., Free PMC Article | 01/31/2024 |
| MicroRNA-23b Plays a Tumor-Suppressive Role in Cutaneous Squamous Cell Carcinoma and Targets Ras-Related Protein RRAS2. | MicroRNA-23b Plays a Tumor-Suppressive Role in Cutaneous Squamous Cell Carcinoma and Targets Ras-Related Protein RRAS2.
Sun C, Mahapatra KD, Elton J, Li C, Fernando W, Lohcharoenkal W, Lapins J, Homey B, Sonkoly E, Pivarcsi A. | 11/22/2023 |
| Characterization of mutant versions of the R-RAS2/TC21 GTPase found in tumors. | Characterization of mutant versions of the R-RAS2/TC21 GTPase found in tumors.
Clavaín L, Fernández-Pisonero I, Movilla N, Lorenzo-Martín LF, Nieto B, Abad A, García-Navas R, Llorente-González C, Sánchez-Martín M, Vicente-Manzanares M, Santos E, Alarcón B, García-Aznar JM, Dosil M, Bustelo XR., Free PMC Article | 02/4/2023 |
| R-Ras subfamily proteins elicit distinct physiologic effects and phosphoproteome alterations in neurofibromin-null MPNST cells. | R-Ras subfamily proteins elicit distinct physiologic effects and phosphoproteome alterations in neurofibromin-null MPNST cells.
Weber SM, Brossier NM, Prechtl A, Barnes S, Wilson LS, Brosius SN, Longo JF, Carroll SL., Free PMC Article | 02/26/2022 |
| RRAS2 knockdown suppresses osteosarcoma progression by inactivating the MEK/ERK signaling pathway. | RRAS2 knockdown suppresses osteosarcoma progression by inactivating the MEK/ERK signaling pathway.
Wang K, Peng K. | 09/19/2020 |
| Germline-Activating RRAS2 Mutations Cause Noonan Syndrome. | Germline-Activating RRAS2 Mutations Cause Noonan Syndrome.
Niihori T, Nagai K, Fujita A, Ohashi H, Okamoto N, Okada S, Harada A, Kihara H, Arbogast T, Funayama R, Shirota M, Nakayama K, Abe T, Inoue SI, Tsai IC, Matsumoto N, Davis EE, Katsanis N, Aoki Y., Free PMC Article | 03/14/2020 |
| Activating Mutations of RRAS2 Cause Noonan Syndrome. | Activating Mutations of RRAS2 Are a Rare Cause of Noonan Syndrome.
Capri Y, Flex E, Krumbach OHF, Carpentieri G, Cecchetti S, Lißewski C, Rezaei Adariani S, Schanze D, Brinkmann J, Piard J, Pantaleoni F, Lepri FR, Goh ES, Chong K, Stieglitz E, Meyer J, Kuechler A, Bramswig NC, Sacharow S, Strullu M, Vial Y, Vignal C, Kensah G, Cuturilo G, Kazemein Jasemi NS, Dvorsky R, Monaghan KG, Vincent LM, Cavé H, Verloes A, Ahmadian MR, Tartaglia M, Zenker M., Free PMC Article | 03/14/2020 |
| Equilibrium dissociation constants were determined for the binding of HRAS, KRAS, NRAS and RRAS2 to the RAS binding (RB) domain of binding proteins. | The RAS-Effector Interface: Isoform-Specific Differences in the Effector Binding Regions.
Nakhaeizadeh H, Amin E, Nakhaei-Rad S, Dvorsky R, Ahmadian MR., Free PMC Article | 07/29/2017 |
| R-Ras2 has a role in both primary breast tumorigenesis and the late metastatic steps of cancer cells in the lung parenchyma. | Contribution of the R-Ras2 GTP-binding protein to primary breast tumorigenesis and late-stage metastatic disease.
Larive RM, Moriggi G, Menacho-Márquez M, Cañamero M, de Álava E, Alarcón B, Dosil M, Bustelo XR. | 07/25/2015 |
| R-RAS2 is overexpressed in the early stages of malignancy in tumors of the human central nervous system. | R-RAS2 overexpression in tumors of the human central nervous system.
Gutierrez-Erlandsson S, Herrero-Vidal P, Fernandez-Alfara M, Hernandez-Garcia S, Gonzalo-Flores S, Mudarra-Rubio A, Fresno M, Cubelos B., Free PMC Article | 07/12/2014 |
| This article is the first study demonstrating expression of TC21 in human skin malignant tumors and suggests that TC21 is more expressed in highly aggressive skin tumors. | Greater expression of TC21/R-ras2 in highly aggressive malignant skin cancer.
Lee JH, Pyon JK, Lee SH, Lee YJ, Kang SG, Kim CH, Kim DW, Nam HS, Park YH, Jeong DJ, Cho MK. | 12/10/2011 |
| Suggest that TC21 promotes cell motility and metastasis by regulating the expression of E-cadherin and N-cadherin in hepatocellular carcinoma and is associated with tumor progression and poor prognosis in HCC. | TC21 promotes cell motility and metastasis by regulating the expression of E-cadherin and N-cadherin in hepatocellular carcinoma.
Luo H, Hao X, Ge C, Zhao F, Zhu M, Chen T, Yao M, He X, Li J. | 01/1/2011 |
| RasGRF GEFs can activate TC21 in all sublocalizations except the Golgi complex. Farnesylated TC21 can be activated by RasGRF1 & RasGRF2, but geranylgeranylated TC21 is unresponsive to RasGRF2. | Structural and spatial determinants regulating TC21 activation by RasGRF family nucleotide exchange factors.
Calvo F, Crespo P., Free PMC Article | 04/12/2010 |
| TC21 directly links antigen receptors to PI(3)K-mediated survival pathways. | Essential function for the GTPase TC21 in homeostatic antigen receptor signaling.
Delgado P, Cubelos B, Calleja E, Martínez-Martín N, Ciprés A, Mérida I, Bellas C, Bustelo XR, Alarcón B. | 01/21/2010 |
| Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) | A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer.
Rokavec M, Schroth W, Amaral SM, Fritz P, Antoniadou L, Glavac D, Simon W, Schwab M, Eichelbaum M, Brauch H. | 01/11/2009 |
| Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) | See all PubMed (2) articlesSNPs in axon guidance pathway genes and susceptibility for Parkinson's disease in the Korean population.
Kim JM, Park SK, Yang JJ, Shin ES, Lee JY, Yun JY, Kim JS, Park SS, Jeon BS. Neither replication nor simulation supports a role for the axon guidance pathway in the genetics of Parkinson's disease.
Li Y, Rowland C, Xiromerisiou G, Lagier RJ, Schrodi SJ, Dradiotis E, Ross D, Bui N, Catanese J, Aggelakis K, Grupe A, Hadjigeorgiou G. | 09/24/2008 |
| TGF-beta and TC21 have roles in tumorigenesis | Signaling pathways regulating TC21-induced tumorigenesis.
Erdogan M, Pozzi A, Bhowmick N, Moses HL, Zent R. | 01/21/2010 |